Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 18.73 AUD 0.32% Market Closed
Market Cap: 2.4B AUD

Intrinsic Value

The intrinsic value of one NEU stock under the Base Case scenario is 12.4 AUD. Compared to the current market price of 18.73 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NEU Intrinsic Value
12.4 AUD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Neuren Pharmaceuticals Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about NEU?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NEU valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Neuren Pharmaceuticals Ltd.

Explain Valuation
Compare NEU to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.

Bull Theses

Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.

Show More Less
How do you feel about NEU?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd

Current Assets 320.2m
Cash & Short-Term Investments 299.5m
Receivables 20.7m
Non-Current Assets 11m
PP&E 25k
Other Non-Current Assets 11m
Efficiency

Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Neuren Pharmaceuticals Ltd

Revenue
228.7m AUD
Operating Expenses
-34.8m AUD
Operating Income
193.9m AUD
Other Expenses
-44.8m AUD
Net Income
149.1m AUD
Fundamental Scores

NEU Profitability Score
Profitability Due Diligence

Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
Exceptional ROIC
Exceptional ROE
79/100
Profitability
Score

Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.

NEU Solvency Score
Solvency Due Diligence

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 26.97 AUD with a low forecast of 21.41 AUD and a high forecast of 33.6 AUD.

Lowest
Price Target
21.41 AUD
14% Upside
Average
Price Target
26.97 AUD
44% Upside
Highest
Price Target
33.6 AUD
79% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Neuren Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NEU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one NEU stock?

The intrinsic value of one NEU stock under the Base Case scenario is 12.4 AUD.

Is NEU stock undervalued or overvalued?

Compared to the current market price of 18.73 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.

Back to Top